Results 21 to 30 of about 588,459 (256)

ROR1 targeting with the antibody drug-conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.

Blood, 2021
Richter syndrome (RS) represents the transformation of chronic lymphocytic leukemia (CLL), typically to an aggressive lymphoma. Treatment options for RS are limited and the disease is often fatal. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is
T. Vaisitti, F. Arruga, Nicoletta Vitale, Th Lee, Mira Ko, A. Chadburn, E. Braggio, A. Di Napoli, Andrea Iannello, J. Allan, L. Miller, B. Lannutti, R. Furman, Katti A. Jessen, S. Deaglio   +14 more
semanticscholar   +1 more source

A Vaccine Against Group B Streptococcus: Recent Advances [PDF]

, 2020
Group B streptococcus (GBS) causes a high burden of neonatal and infant disease globally. Implementing a vaccine for pregnant women is a promising strategy to prevent neonatal and infant GBS disease and has been identified as a priority by the World ...
Carreras-Abad, C, Heath, PT, Le Doare, K, Ramkhelawon, L   +3 more
core   +2 more sources

Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors.

Antibody Therapeutics, 2021
Background ERBB2 is a proto-oncogene of multiple cancers including breast and gastric cancers with HER2 protein overexpression or gene amplification and has been proven clinically as a valid target for these cancers.
Hu Li, Xiao Zhang, Zhenyi Xu, Lingrui Li, Wenchao Liu, Zhenyu Dai, Zhongrun Zhao, Lili Xiao, Hongfeng Li, Chaohong Hu   +9 more
semanticscholar   +1 more source

Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. [PDF]

, 2014
Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene. It is an intracellular calcium signal transducer that is differentially expressed in many cancers. It signals cells for self-renewal, proliferation, invasion, and survival.
Bonavida, Benjamin, Shvartsur, Anna
core   +5 more sources

Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE).

Journal of Clinical Oncology, 2010
1095 Background: GPNMB (osteoactivin), a novel glycoprotein expressed in 25-40% of breast cancers as well as various tumor types, promotes BC metastases in vivo and is a prognostic marker of poor outcome in BC patients (pts). CDX-011, an ADC consisting of a fully-human monoclonal antibody to GPNMB (CR011) conjugated via enzyme-sensitive linker to the ...
Saleh, Mansoor, Bendell, J. C., Rose, A., Siegel, P., Hart, L. L., Sirpal, S., Jones, S. F., Crowley, E., Simantov, R., Vahdat, L. T.   +9 more
openaire   +3 more sources

Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.

Neuro-Oncology, 2021
BACKGROUND Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a ...
B. Marin, K. Porath, Sonia Jain, Minjee Kim, Jason E. Conage-Pough, J. Oh, Caitlyn L. Miller, Surabhi Talele, G. Kitange, Shulan Tian, Danielle M. Burgenske, A. Mladek, Shiv K. Gupta, P. Decker, M. McMinn, S. Stopka, M. Regan, Lihong He, B. Carlson, K. Bakken, T. Burns, I. Parney, C. Giannini, N. Agar, J. Eckel-Passow, J. Cochran, W. Elmquist, R. Vaubel, F. White, J. Sarkaria   +29 more
semanticscholar   +1 more source

Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase. [PDF]

, 2019
Nucleic Acid Therapeutics (NATs), including siRNAs and AntiSense Oligonucleotides (ASOs), have great potential to drug the undruggable genome. Targeting siRNAs and ASOs to specific cell types of interest has driven dramatic improvement in efficacy and ...
Cui, Xianshu, Dowdy, Steven F, Huggins, Ian J, Jadhav, Satish, Medina, Carlos A, Springer, Aaron D, van den Berg, Arjen   +6 more
core   +1 more source

A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development

Antibodies, 2019
Antibodies, antibody-like molecules, and therapeutics incorporating antibodies as a targeting moiety, such as antibody-drug conjugates, offer significant potential for the development of highly efficacious drugs against a wide range of disorders. Despite
Gareth D. Healey, Asa Frostell, Tim Fagge, Deyarina Gonzalez, R. Steven Conlan   +4 more
doaj   +1 more source

A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. [PDF]

, 2015
Although recent methods for the engineering of antibody-drug conjugates (ADCs) have gone some way to addressing the challenging issues of ADC construction, significant hurdles still remain.
Caddick, S, Chester, KA, Chudasama, V, Maruani, A, Miranda, E, Smith, ME   +5 more
core   +1 more source

Antibody drug conjugates

Indian Journal of Medical and Paediatric Oncology, 2020
Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj   +1 more source